GenSight Biologics S.A.
SIGHT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.08 | 1.18 | 0.25 |
| FCF Yield | -50.04% | -111.01% | -21.83% | -6.84% |
| EV / EBITDA | -2.88 | -2.01 | -5.89 | -8.59 |
| Quality | ||||
| ROIC | -777.45% | -2,430.02% | -202.80% | -70.64% |
| Gross Margin | 100.00% | 236.78% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.92 | 0.94 | 1.22 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.55% | -37.84% | -16.24% | 96.07% |
| Free Cash Flow Growth | 47.56% | 27.44% | -98.04% | -14.09% |
| Safety | ||||
| Net Debt / EBITDA | -1.13 | -0.98 | -0.08 | 1.24 |
| Interest Coverage | -10.18 | -9.42 | -10.50 | -12.99 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1,733.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.14 | 1,187.12 | 493.36 | 52.16 |